Skip to main content

Peer Review reports

From: Oxindole–benzothiazole hybrids as CDK2 inhibitors and anticancer agents: design, synthesis and biological evaluation

Original Submission
7 Apr 2024 Submitted Original manuscript
11 Apr 2024 Author responded Author comments - Heba T. Abdel-Mohsen
4 May 2024 Reviewed Reviewer Report
10 May 2024 Reviewed Reviewer Report
13 May 2024 Reviewed Reviewer Report
30 Jun 2024 Author responded Author comments - Heba T. Abdel-Mohsen
Resubmission - Version 2
11 Apr 2024 Submitted Manuscript version 2
7 Jul 2024 Reviewed Reviewer Report
13 Jul 2024 Reviewed Reviewer Report
9 Aug 2024 Author responded Author comments - Heba T. Abdel-Mohsen
Resubmission - Version 3
9 Aug 2024 Submitted Manuscript version 3
16 Aug 2024 Author responded Author comments - Heba T. Abdel-Mohsen
Resubmission - Version 4
16 Aug 2024 Submitted Manuscript version 4
20 Aug 2024 Author responded Author comments - Heba T. Abdel-Mohsen
Resubmission - Version 5
20 Aug 2024 Submitted Manuscript version 5
Publishing
21 Aug 2024 Editorially accepted
13 Sep 2024 Article published 10.1186/s13065-024-01277-1

You can find further information about peer review here.

Back to article page